$ONC
BeiGene, Ltd.

2023 Q4 Form 10-Q Financial Statement

#000165130823000165 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $4.548B $781.3M
YoY Change 68.6% 101.56%
Cost Of Revenue $819.4M $96.31M
YoY Change 63.26% 25.82%
Gross Profit $3.729B $685.0M
YoY Change 69.82% 120.2%
Gross Profit Margin 81.98% 87.67%
Selling, General & Admin $2.958B $364.4M
YoY Change 24.94% 12.86%
% of Gross Profit 79.32% 53.2%
Research & Development $3.636B $453.3M
YoY Change 15.99% 6.31%
% of Gross Profit 97.51% 66.17%
Depreciation & Amortization $19.24M
YoY Change 26.48%
% of Gross Profit 2.81%
Operating Expenses $6.589B $817.7M
YoY Change 19.39% 9.13%
Operating Profit -$2.860B -$134.0M
YoY Change -13.93% -69.44%
Interest Expense $236.1M -$12.33M
YoY Change -4.25% -98.56%
% of Operating Profit
Other Income/Expense, Net -$902.0K $336.7M
YoY Change -26.0% -367.95%
Pretax Income -$2.625B $229.3M
YoY Change -14.71% -141.6%
Income Tax $212.9M $13.93M
% Of Pretax Income 6.07%
Net Earnings -$2.838B $215.4M
YoY Change -11.55% -138.64%
Net Earnings / Revenue -62.39% 27.57%
Basic Earnings Per Share $0.16
Diluted Earnings Per Share -$2.11 $0.15
COMMON SHARES
Basic Shares Outstanding 1.359B shares 1.376B shares
Diluted Shares Outstanding 1.390B shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.55B $22.34B
YoY Change -15.82% -22.89%
Cash & Equivalents $3.172B $3.067B
Short-Term Investments $7.515B $4.432B
Other Short-Term Assets $1.083B $2.407B
YoY Change -82.36% -71.74%
Inventory $416.1M $316.9M
Prepaid Expenses
Receivables $358.0M $309.1M
Other Receivables $685.6M $309.2M
Total Short-Term Assets $4.203B $4.054B
YoY Change -19.27% -29.49%
LONG-TERM ASSETS
Property, Plant & Equipment $1.324B $1.178B
YoY Change 56.53% 72.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $25.98M $27.33M
YoY Change -6.24% 5.96%
Other Assets $125.4M $140.9M
YoY Change -26.44% 0.25%
Total Long-Term Assets $1.602B $1.471B
YoY Change 36.65% 50.62%
TOTAL ASSETS
Total Short-Term Assets $4.203B $4.054B
Total Long-Term Assets $1.602B $1.471B
Total Assets $5.805B $5.525B
YoY Change -9.0% -17.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $315.1M $341.9M
YoY Change 6.9% 35.62%
Accrued Expenses $693.7M $505.8M
YoY Change 48.44% 23.3%
Deferred Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Short-Term Debt $4.684B $2.224B
YoY Change 112.63% -25.29%
Long-Term Debt Due 4.886B cnies 2.399B cnies
YoY Change 115.34% 443.6%
Total Short-Term Liabilities $1.810B $1.283B
YoY Change 23.26% -9.07%
LONG-TERM LIABILITIES
Long-Term Debt 1.403B cnies 1.478B cnies
YoY Change -2.76% 610.55%
Other Long-Term Liabilities $50.51M $41.99M
YoY Change 9.58% -7.05%
Total Long-Term Liabilities $457.8M $478.3M
YoY Change -13.19% -27.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.810B $1.283B
Total Long-Term Liabilities $457.8M $478.3M
Total Liabilities $2.268B $1.762B
YoY Change 13.63% -14.93%
SHAREHOLDERS EQUITY
Retained Earnings -$7.962B -$7.594B
YoY Change 12.45% 14.46%
Common Stock $135.0K $135.0K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.537B $3.763B
YoY Change
Total Liabilities & Shareholders Equity $5.805B $5.525B
YoY Change -9.0% -17.86%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.838B $215.4M
YoY Change -11.55% -138.64%
Depreciation, Depletion And Amortization $19.24M
YoY Change 26.48%
Cash From Operating Activities -$2.392B -$297.8M
YoY Change 78.37% -90.46%
INVESTING ACTIVITIES
Capital Expenditures $1.009B $1.180B
YoY Change 17.14% -263.1%
Acquisitions
YoY Change
Other Investing Activities -$1.697B $1.359B
YoY Change -55.51% -7.83%
Cash From Investing Activities -$2.706B $178.1M
YoY Change -42.12% -76.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.308B -597.0M
YoY Change -358.94% -179.57%
NET CHANGE
Cash From Operating Activities -2.392B -297.8M
Cash From Investing Activities -2.706B 178.1M
Cash From Financing Activities 2.308B -597.0M
Net Change In Cash -2.790B -716.7M
YoY Change -59.61% -55.79%
FREE CASH FLOW
Cash From Operating Activities -$2.392B -$297.8M
Capital Expenditures $1.009B $1.180B
Free Cash Flow -$3.401B -$1.478B
YoY Change 54.42% -38.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3067336000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3869564000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
11548000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
196000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
106989000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
665251000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
309079000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
173168000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
316929000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
282346000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
241661000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
216553000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
4053542000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
5207078000 usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1356140180 shares
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1824370000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1035826000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
274088000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1284607000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1194485000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1087954000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
948868000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-823941000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1321043000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
57735000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
34261000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
291142000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-243290000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-475064000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1530072000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39091000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28408000 usd
us-gaap Net Income Loss
NetIncomeLoss
-514155000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1558480000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1337976853 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1390331833 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1337976853 shares
bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
-15.14
CY2023Q3 bgne Earnings Per American Depository Share Diluted
EarningsPerAmericanDepositoryShareDiluted
2.01
bgne Earnings Per American Depository Share Diluted
EarningsPerAmericanDepositoryShareDiluted
-4.92
us-gaap Net Income Loss
NetIncomeLoss
-514155000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1558480000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-75732000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-581669000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1737953000 usd
bgne Amortization Of Research And Development Financing Liability
AmortizationOfResearchAndDevelopmentFinancingLiability
-38569000 usd
bgne Amortization Of Research And Development Financing Liability
AmortizationOfResearchAndDevelopmentFinancingLiability
-70389000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
735000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
380000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4382887000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1178038000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
845946000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
98742000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109960000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
53657000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40616000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140900000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
175690000 usd
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
1471337000 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1172212000 usd
CY2023Q3 us-gaap Assets
Assets
5524879000 usd
CY2022Q4 us-gaap Assets
Assets
6379290000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
341857000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
294781000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
505824000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
467352000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
213861000 usd
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
20158000 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
25189000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23246000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24041000 usd
CY2023Q3 bgne Research And Development Cost Share Liability Current Portion
ResearchAndDevelopmentCostShareLiabilityCurrentPortion
63652000 usd
CY2022Q4 bgne Research And Development Cost Share Liability Current Portion
ResearchAndDevelopmentCostShareLiabilityCurrentPortion
114335000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
328560000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
328969000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1283297000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1468528000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
202491000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
209148000 usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
300000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
42026000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25474000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34517000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16358000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
15996000 usd
CY2023Q3 bgne Research And Development Cost Share Liability Noncurrent Portion
ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion
191739000 usd
CY2022Q4 bgne Research And Development Cost Share Liability Noncurrent Portion
ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion
179625000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41986000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46095000 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
478348000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
527407000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1761645000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1995935000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
9500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
9500000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1352997624 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1352997624 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1356140180 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
135000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
135000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11502527000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11540979000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-144931000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-77417000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7594497000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7080342000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3763234000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4383355000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5524879000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6379290000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
781308000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
387628000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
96309000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
76543000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
212953000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
453259000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
426363000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
364421000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
322892000 usd
CY2023Q3 bgne Amortization Of Intangible Assets Included In Operating Expenses
AmortizationOfIntangibleAssetsIncludedInOperatingExpenses
1287000 usd
CY2022Q3 bgne Amortization Of Intangible Assets Included In Operating Expenses
AmortizationOfIntangibleAssetsIncludedInOperatingExpenses
187000 usd
bgne Amortization Of Intangible Assets Included In Operating Expenses
AmortizationOfIntangibleAssetsIncludedInOperatingExpenses
1662000 usd
bgne Amortization Of Intangible Assets Included In Operating Expenses
AmortizationOfIntangibleAssetsIncludedInOperatingExpenses
563000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
915276000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
825985000 usd
us-gaap Costs And Expenses
CostsAndExpenses
2648311000 usd
us-gaap Costs And Expenses
CostsAndExpenses
2356869000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-133968000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-438357000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
26649000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
12759000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
336657000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-125640000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
229338000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-551238000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13925000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6318000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
215413000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-557556000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1360716279 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1345303747 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1358392470 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1345303747 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1358392470 shares
CY2023Q3 bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
2.06
CY2022Q3 bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
-5.39
bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
-4.92
CY2022Q3 bgne Earnings Per American Depository Share Diluted
EarningsPerAmericanDepositoryShareDiluted
-5.39
bgne Earnings Per American Depository Share Diluted
EarningsPerAmericanDepositoryShareDiluted
-15.14
CY2023Q3 bgne Weighted Average Number Of American Depository Shares Outstanding Basic
WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic
104670483 shares
CY2022Q3 bgne Weighted Average Number Of American Depository Shares Outstanding Basic
WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic
103484904 shares
bgne Weighted Average Number Of American Depository Shares Outstanding Basic
WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic
104491728 shares
bgne Weighted Average Number Of American Depository Shares Outstanding Basic
WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic
102921296 shares
CY2023Q3 bgne Weighted Average Number Of American Depository Shares Outstanding Diluted
WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted
106948603 shares
CY2022Q3 bgne Weighted Average Number Of American Depository Shares Outstanding Diluted
WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted
103484904 shares
bgne Weighted Average Number Of American Depository Shares Outstanding Diluted
WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted
104491728 shares
bgne Weighted Average Number Of American Depository Shares Outstanding Diluted
WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted
102921296 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
215413000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-557556000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2559000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-80326000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-168411000 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1315000 usd
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1253000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8218000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-11062000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
214169000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-636629000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-12273000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-16413000 usd
bgne Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
15000000 usd
bgne Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
20000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
362917000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
822000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
7762000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
143511000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-284717000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
52371000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
75632000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
17598000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-30325000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31366000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4203000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
50089000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1628000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-255587000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-112820000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
55000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
167000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-935815000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1178428000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
404937000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
204076000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9413000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
15581000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
14735000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
567519000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1352398000 usd
bgne Payments To Purchase In Process Research And Development
PaymentsToPurchaseInProcessResearchAndDevelopment
15000000 usd
bgne Payments To Purchase In Process Research And Development
PaymentsToPurchaseInProcessResearchAndDevelopment
95000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
122588000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1038587000 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
22502000 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
37372000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
8462000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
162614000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
163774000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
159576000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
145428000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
52352000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
35677000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69430000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91395000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-50348000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-133929000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-794145000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-182375000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3875037000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3080892000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4200512000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3067336000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4197132000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
11548000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
191000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2008000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3189000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
42516000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25006000 usd
us-gaap Interest Paid Net
InterestPaidNet
15893000 usd
us-gaap Interest Paid Net
InterestPaidNet
19865000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
107611000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
47310000 usd
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
9384000 usd
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4383355000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
28657000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75322000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
18403000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-348431000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4157306000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3692000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
103371000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-84673000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-381137000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3798559000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
17419000 usd
CY2023Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
362917000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
96004000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1244000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6132563000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
152000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
11880000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
65555000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-496000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-435198000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
5774152000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
7092000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
81305000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-99904000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-565726000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
5196919000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
16705000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
78176000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-79073000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-557556000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
4655171000 usd
CY2023Q3 bgne Number Of Approved Medicines
NumberOfApprovedMedicines
3 medicine
CY2023Q3 bgne Number Of Approved Medicines Company Has Rights To
NumberOfApprovedMedicinesCompanyHasRightsTo
14 medicine
CY2023Q3 bgne Clinical Trials Conducted
ClinicalTrialsConducted
120 trial
CY2023Q3 bgne Number Of Patients
NumberOfPatients
21000 patient
CY2023Q3 bgne Number Of Regions
NumberOfRegions
45 region
CY2023Q3 bgne Product Candidate
ProductCandidate
3 product
CY2023Q3 dei Entity Number Of Employees
EntityNumberOfEmployees
10000 employee
bgne Upfront And Milestone Payments
UpfrontAndMilestonePayments
20000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and determining the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates.</span></div>
CY2023Q3 bgne Debt Securities Available For Sale Excluding Accrued Interest Number Of Issuing Companies Held
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNumberOfIssuingCompaniesHeld
2 company
CY2022Q1 bgne Number Of Products Initiated Marketing And Promotion
NumberOfProductsInitiatedMarketingAndPromotion
5 product
CY2022Q1 bgne Number Of Products Initiated Marketing And Promotion
NumberOfProductsInitiatedMarketingAndPromotion
5 product
CY2023Q3 bgne Number Of Ongoing Trials
NumberOfOngoingTrials
2 trial
CY2023Q3 bgne Reimbursement Expense
ReimbursementExpense
11089000 usd
CY2022Q3 bgne Reimbursement Expense
ReimbursementExpense
14660000 usd
bgne Reimbursement Expense
ReimbursementExpense
37981000 usd
bgne Reimbursement Expense
ReimbursementExpense
36926000 usd
CY2023Q3 bgne Upfront And Milestone Payments
UpfrontAndMilestonePayments
24379000 usd
CY2022Q3 bgne Upfront And Milestone Payments
UpfrontAndMilestonePayments
20000000 usd
bgne Upfront And Milestone Payments
UpfrontAndMilestonePayments
33612000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
11548000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
196000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2008000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5277000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
13556000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
5473000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
107783000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
794000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
106989000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
674262000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9011000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
665251000 usd
CY2023Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
57631000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
57054000 usd
CY2023Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
5522000 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
4699000 usd
CY2022Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
4441000 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
5065000 usd
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
27325000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
27710000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
15214000 usd
us-gaap Depreciation
Depreciation
45255000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
66712000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13055000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
53657000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
94031000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
88957000 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
40023000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
20886000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
182875000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
172503000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
316929000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
282346000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
767805000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
723789000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
220835000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
171470000 usd
CY2023Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
631068000 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
293627000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1178038000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
845946000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
19242000 usd
us-gaap Depreciation
Depreciation
59574000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
49551000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8935000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40616000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2268000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
987000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4282000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3007000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3398000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6240000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6240000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
6240000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
6240000 usd
CY2023Q3 bgne Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
25299000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
53657000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13925000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39091000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6318000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28408000 usd
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13910000 usd
CY2023Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1386000 usd
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
2355000 usd
CY2023Q3 bgne Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
73036000 usd
CY2022Q4 bgne Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
71488000 usd
CY2023Q3 bgne Prepaid Manufacturing Costs
PrepaidManufacturingCosts
71993000 usd
CY2022Q4 bgne Prepaid Manufacturing Costs
PrepaidManufacturingCosts
58950000 usd
CY2023Q3 us-gaap Prepaid Taxes
PrepaidTaxes
19568000 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
20478000 usd
CY2023Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
43911000 usd
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
22777000 usd
CY2023Q3 bgne Prepaid Commercial Current
PrepaidCommercialCurrent
1089000 usd
CY2022Q4 bgne Prepaid Commercial Current
PrepaidCommercialCurrent
1461000 usd
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
1628000 usd
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
3039000 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
6492000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3664000 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
23944000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34696000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
241661000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
216553000 usd
CY2023Q3 bgne Prepayment Of Long Term Asset
PrepaymentOfLongTermAsset
12343000 usd
CY2022Q4 bgne Prepayment Of Long Term Asset
PrepaymentOfLongTermAsset
22025000 usd
CY2023Q3 bgne Prepaid Supply Cost
PrepaidSupplyCost
28290000 usd
CY2022Q4 bgne Prepaid Supply Cost
PrepaidSupplyCost
48642000 usd
CY2023Q3 us-gaap Value Added Tax Receivable Noncurrent
ValueAddedTaxReceivableNoncurrent
2034000 usd
CY2022Q4 us-gaap Value Added Tax Receivable Noncurrent
ValueAddedTaxReceivableNoncurrent
804000 usd
CY2023Q3 bgne Rental Deposits And Other
RentalDepositsAndOther
6944000 usd
CY2022Q4 bgne Rental Deposits And Other
RentalDepositsAndOther
7054000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2008000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5277000 usd
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
89281000 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
91779000 usd
CY2023Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
0 usd
CY2022Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
109000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140900000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
175690000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
173980000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
184775000 usd
CY2023Q3 bgne Accrued Liabilities External Research And Development
AccruedLiabilitiesExternalResearchAndDevelopment
92710000 usd
CY2022Q4 bgne Accrued Liabilities External Research And Development
AccruedLiabilitiesExternalResearchAndDevelopment
139168000 usd
CY2023Q3 bgne Accrued Expenses Commercial Activities
AccruedExpensesCommercialActivities
60692000 usd
CY2022Q4 bgne Accrued Expenses Commercial Activities
AccruedExpensesCommercialActivities
51806000 usd
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
23191000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
18815000 usd
CY2023Q3 bgne Accrued Sales Rebates And Returns Current
AccruedSalesRebatesAndReturnsCurrent
112256000 usd
CY2022Q4 bgne Accrued Sales Rebates And Returns Current
AccruedSalesRebatesAndReturnsCurrent
41817000 usd
CY2023Q3 bgne Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
42995000 usd
CY2022Q4 bgne Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
30971000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
505824000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
467352000 usd
CY2023Q3 bgne Government Grants Or Incentives Received And Deferred Noncurrent
GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent
33909000 usd
CY2022Q4 bgne Government Grants Or Incentives Received And Deferred Noncurrent
GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent
38176000 usd
CY2023Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
7830000 usd
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
7760000 usd
CY2023Q3 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
247000 usd
CY2022Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
159000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41986000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46095000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
328560000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2398773000 cny
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
328969000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2268905000 cny
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
202491000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1478357000 cny
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
209148000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1442500000 cny
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
215413000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-557556000 usd
us-gaap Net Income Loss
NetIncomeLoss
-514155000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1558480000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1360716279 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1345303747 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1358392470 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1337976853 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
29615554 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1390331833 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1345303747 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1358392470 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1337976853 shares
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
96119000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
78176000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
274836000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
225036000 usd
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-67514000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-67514000 usd
CY2023Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
362917000 usd
CY2023Q3 bgne Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage
RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage
0.10
CY2023Q3 bgne Restricted Net Assets Required Statutory Reserve As Percentage Of Registered Capital
RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital
0.50
CY2023Q3 bgne Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage
RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage
0.10
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
131693000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
781308000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
387628000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1824370000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1035826000 usd
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001651308-23-000165-index-headers.html Edgar Link pending
0001651308-23-000165-index.html Edgar Link pending
0001651308-23-000165.txt Edgar Link pending
0001651308-23-000165-xbrl.zip Edgar Link pending
bgne-20230930.htm Edgar Link pending
bgne-20230930.xsd Edgar Link pending
bgne-20230930_g1.jpg Edgar Link pending
exhibit101.htm Edgar Link pending
bgne-20230930_cal.xml Edgar Link unprocessable
bgne-20230930_def.xml Edgar Link unprocessable
bgne-20230930_pre.xml Edgar Link unprocessable
bgne-20230930_lab.xml Edgar Link unprocessable
bgne-20230930_htm.xml Edgar Link completed
exhibit102.htm Edgar Link pending
exhibit311-2023q3.htm Edgar Link pending
exhibit312-2023q3.htm Edgar Link pending
exhibit321-2023q3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable